Adma Biologics ADMA
Nasdaq · Biological Products, (No Diagnostic Substances) · $3.1BNo closes on file for ADMA yet.
Data provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.
The numbers
fiscal 2025, as filed with the SEC · 66-metric EOD snapshot via DatabentoOperating leverage — margins
| Line Item (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY Δ | 4Y CAGR | Trend |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $80.9M | $154.1M | $258.2M | $426.5M | $510.2M | +19.6% | +58.4% | |
| Cost of Revenue (COGS) | $79.8M | $118.8M | $169.3M | $206.9M | $217.4M | +5.1% | +28.5% | |
| Gross Profit | $1.2M | $35.3M | $88.9M | $219.6M | $292.8M | +33.3% | +297.5% | |
| Research & Development (R&D) | $3.6M | $3.6M | $3.3M | $1.8M | $4.8M | +162.7% | +6.9% | |
| Selling, General & Admin (SG&A) | $42.9M | $52.5M | $59.0M | $74.1M | $91.6M | +23.5% | +20.9% | |
| Total Operating Expenses | $59.5M | $74.6M | $67.3M | $80.6M | $101.3M | +25.8% | +14.2% | |
| Operating Income (EBIT) | $-58.4M | $-39.4M | $21.6M | $139.0M | $191.4M | +37.7% | — | |
| Interest Expense | $13.1M | $19.3M | $25.0M | $13.9M | $7.1M | −49.0% | −14.1% | |
| Income Tax Expense | $0 | $0 | $0 | $-72.0M | $35.7M | +149.6% | — | |
| GAAP Net Income | $-71.7M | $-65.9M | $-28.2M | $197.7M | $146.9M | −25.7% | — | |
| Diluted EPS | $-0.51 | $-0.33 | $-0.13 | $0.81 | $0.60 | −25.9% | — | |
| Diluted Shares | 139.6M | 197.9M | 224.0M | 243.3M | 244.9M | +0.6% | +15.1% | |
| Balance Sheet | ||||||||
| Cash & Equivalents | $51.1M | $86.5M | $51.4M | $103.1M | $87.6M | −15.0% | +14.4% | |
| Inventory | $124.7M | $163.3M | $172.9M | $170.2M | $206.5M | +21.3% | +13.4% | |
| Total Current Assets | $208.7M | $270.4M | $257.0M | $331.4M | $466.5M | +40.8% | +22.3% | |
| Total Assets | $276.3M | $348.5M | $329.2M | $488.7M | $624.2M | +27.7% | +22.6% | |
| Total Current Liabilities | $30.4M | $39.3M | $49.8M | $55.5M | $69.5M | +25.2% | +23.0% | |
| Total Debt (Short + Long Term) | $4.2M | $4.2M | $4.2M | $72.3M | $75.0M | +3.6% | +105.3% | |
| Total Liabilities | $135.1M | $196.5M | $194.0M | $139.7M | $146.9M | +5.2% | +2.1% | |
| Stockholders' Equity | $141.2M | $152.0M | $135.2M | $349.0M | $477.3M | +36.8% | +35.6% | |
| Net Cash / (Net Debt) | $46.9M | $82.3M | $47.1M | $30.8M | $12.7M | −58.9% | −27.9% | |
| Invested Capital | $94.3M | $69.7M | $88.1M | $318.2M | $464.6M | +46.0% | +49.0% | |
| Cash Flow & Capital Allocation | ||||||||
| Operating Cash Flow (OCF) | $-112.4M | $-59.5M | $8.8M | $118.7M | $50.4M | −57.5% | — | |
| Depreciation & Amortization (D&A) | $4.8M | $6.4M | $7.6M | $7.7M | $8.0M | +3.9% | +13.6% | |
| Stock-Based Compensation (SBC) | $3.5M | $5.2M | $6.2M | $13.6M | $20.0M | +47.1% | +54.8% | |
| Capital Expenditures (CapEx) | $13.5M | $13.9M | $4.8M | $8.2M | $22.6M | +174.4% | +13.7% | |
| Free Cash Flow (FCF) | $-125.9M | $-73.4M | $4.0M | $110.4M | $27.8M | −74.8% | — | |
| True FCF (ex-SBC Owner Cash) | $-129.4M | $-78.6M | $-2.2M | $96.8M | $7.8M | −91.9% | — | |
| Share Repurchases (Buybacks) | — | — | $0 | $0 | $31.9M | — | — | |
Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.